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listic sensitivity analyses were performed to assess the robustness of the results.
RESULTS: The cost-effectiveness model showed a gain of 0.29 (95% CI: 0.19 - 0.40)
QALY in individuals with varenicline therapy over NRT for a 57 year old person with
CVD. Incremental costs associated with the smoking cessation program amounted
to €67 whereas incremental costs associated with additional medical costs in the
extra lifetime equalled €456 on average. In total, the incremental cost of varenicline
therapy compared to NRT was €523 (€276 - €815). Corresponding incremental cost-
effectiveness ratio was estimated at €1,817/QALY (€1171/QALY - €2440/QALY) for
varenicline vs. nicotine replacement therapy. CONCLUSIONS: The model suggests
that varenicline therapy in people with CVD is cost-effective and provides value-
for-money compared to NRT.
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OBJECTIVES: To determine the cost-effectiveness of lipid lowering therapy in the
secondary prevention of cardiovascular events in the Philippines. METHODS: A
cost-utility analysis was performed using Markov modeling in the secondary pre-
vention setting. The models incorporated efficacy of lipid lowering therapy dem-
onstrated in randomized controlled trials and mortality rates obtained from local
life tables. Average and incremental cost-effectiveness ratios (ACERs and ICERs)
were obtained for Simvastatin, Atorvastatin, Pravastatin, and Gemfibrozil. The
costs of the following were included: medications, laboratory examinations, con-
sultation (professional fees) and related expenses and production losses. The costs
were expressed in current or nominal prices as of the 1st quarter of 2010 (Philippine
peso). Utility was expressed in quality-adjusted life years gained (QALYs). Sensi-
tivity analyses were performed using variations in the cost centers, discount rates,
starting age and differences in utility weights for stroke. RESULTS: In the analysis
using the lower-priced generic counterparts, therapy using 40 mg Simvastatin
daily was the most cost-effective option compared to the other therapies, while
Pravastatin 40 mg daily was the most cost-effective alternative if the higher-priced
innovator drugs were used. In all sensitivity analyses, Gemfibrozil was strongly
dominated by the statins. CONCLUSIONS: In the secondary prevention setting,
Simvastatin or Pravastatin were the most cost-effective options compared to Ator-
vastatin and Gemfibrozil in the Philippines. Gemfibrozil was strongly dominated by
the statins.
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OBJECTIVES: To assess the cost-effectiveness of rivaroxaban versus acenocumarol
and a real-world prescription pattern (RWP), for prevention of stroke in atrial fibril-
lation (AF) patients in the Spanish NHS setting. METHODS: A Markov model was
developed with health and treatment states describing the management and con-
sequences of AF. Patients enter the model with stable non-valvular AF are treated
withoralanti-coagulantsoraRWP(53.7%patients treatedwithacenocumarol,32.6%with
acetylsalicylic acid and 13.7% untreated, data extracted from a Longitudinal Patient Data-
base) and progress between states according to transition probabilities derived from the
ROCKET-AF study (safety-on-treatment dataset), observational data and a network meta-
analysis. Costs (drug, monitoring and events costs) and outcomes were assigned to each
state, and used to estimate costs per quality-adjusted-life-year gained (QALY). A disutility
for acenocumarol was included. The cycle length was 3 months and time horizon was set
to describe the lifetime of the patients (3% annual discounting rate for costs and benefits).
A sub-population analysis compared rivaroxaban to acenocumarol in patients with poor
INR control (patients who spend less than 60% of time in therapeutic range). Probabilistic
sensitivity analysis (PSA) was conducted to test the robustness of results. RESULTS: In
base-case, drug acquisition costs were higher in rivaroxaban group (€5,117 incre-
mental cost), while cost savings were estimated for monitoring and events avoided
compared to acenocumarol group (-€2,091 and -€522, respectively) and RWP
(-€1,385 and -€2,366, respectively) with a higher effectiveness (0.20 and 0.51 incre-
mental QALYs, respectively). ICERs were €11,274/QALY vs. acenocumarol and
€3,986/QALY vs. RWP. In poor INR controlled group the ICER was €2,144/QALY. PSA
indicated a high probability of rivaroxaban being cost-effective at a threshold of
€30,000/QALY. CONCLUSIONS: In the Spanish setting rivaroxaban is a cost-effec-
tive treatment option compared to VKA in the total AF population and particularly
in poorly controlled VKA patients.
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OBJECTIVES: To estimate the cost effectiveness of rivaroxaban compared to war-
farin for the prophylaxis of stroke in patients with atrial fibrillation (AF) from a
payer perspective in Slovakia. METHODS: A Markov model based on the results of
a large double-blind, randomized controlled clinical trial (ROCKET AF) has been
developed and adapted to the Slovakian settings. The model consists of health
states covering the management and outcomes of AF. Costs and utilities were
assigned to each state as well as to the warfarin therapy to reflect the burden of this
therapy (regular INR monitoring, dietary restrictions). Local cost data were based
on published local data, official price lists, clinical guidelines and product labels.
Data for utilities were derived from literature. The time horizon reflected a pa-
tient’s life-time. To estimate the incremental costs per quality-adjusted life year
gained (ICER) a discount rate of 5% was applied to costs and effects according to
official guidelines. One-way and probabilistic sensitivity analyses were performed.
RESULTS: Rivaroxaban was cost-effective compared to warfarin with an ICER of
17.432 € (incremental QALYs of 0,22 and incremental costs of 3 835 €). The one-way
and probabilistic sensitivity analyses indicated that these results are fairly robust
for most parameters and that rivaroxaban is cost-effective in the majority of
simulations. CONCLUSIONS: Prevention of stroke with rivaroxaban in population
of AF patients is cost-effective when compared to warfarin in the Slovakian setting.
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OBJECTIVES: To conduct an economic analysis of the risk assessment of ischemic
heart disease (IHD) with Cardio inCode (adding the genetic risk to the functions of
REGICOR and Framingham) compared with the standard method (using only the
functions).METHODS:A Markov model was developed with 7 states of health (low,
intermediate, high IHD risk; IHD event, recurrent IHD, chronic IHD and death). The
reclassification of IHD risk derived from genetic information and transition prob-
abilities between states were obtained from a validation study conducted in co-
horts of REGICOR (Spain) and Framingham (USA). It was assumed that patients
classified as intermediate risk by the standard method could be evaluated and their
risk reclassified with Cardio inCode. The utilities and costs of Markov states were
obtained from the literature and Spanish sources. The analysis was done from the
perspective of the National Health System, for a time-life horizon. An annual dis-
count rate of 3.5% for costs and benefits was applied. RESULTS: For a Cardio inCode
price of 400 €, the cost per quality-adjusted life year (QALY) gained compared with
the standard method (incremental cost effectiveness ratio, ICER) would be € 12,957
and € 21,328 in REGICOR and Framingham cohorts, respectively. The threshold
price of Cardio inCode to reach the ICER threshold generally accepted in Spain
(30,000 €/QALY) would range between € 668 and € 836. The greatest benefit occurred
in the subgroup of patients with intermediate-high risk, with a high risk reclassi-
fication of 22.8% of patients and an ICER of € 1,650/QALY and € 5,893/QALY (REGI-
COR and Framingham cohorts). Sensitivity analyses confirmed the stability of the
study results. CONCLUSIONS: Cardio inCode is a cost-effective genetic option in
IHD risk assessment compared with the standard method.
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OBJECTIVES: To combine and supplement public national registries and patient
level chart data in order to describe and compare demographics, treatment pat-
terns and mortality in patients with chronic thromboembolic pulmonary hyper-
tension (CTEPH), a rare disease. METHODS: Using the national Swedish prescrip-
tion, inpatient and cause of death registries, CTEPH patients were identified via
algorithms about drug prescriptions and diagnostic/procedural codes. A second
cohort, identified from medical charts of diagnosed CTEPH patients treated in spe-
cialized treatment centers across five European countries was abstracted retro-
spectively. Descriptive statistics and potential areas of complementary informa-
tion are described. RESULTS: Basic data on demographic and clinical
characteristics, medication and selected health resource consumption data were
found to have sufficient overlap to allow the comparison between cohorts. From
Swedish registries, 94 CTEPH patients were identified. In the medical charts, 116
patients were included. Mean age of 61.414.5 years in registry patients was 6.1
years younger than the chart cohort (67.512.3). Both cohorts were predominantly
female (registry 52%, chart cohort 61%). Medications for pulmonary arterial hyper-
tension were common in both datasets: endothelin receptor antagonists were 45%
in registry versus 60% in chart, followed by phosphodiesterase-5 inhibitors (regis-
try 36%, chart 32%), and prostacyclins were less common (5-6%). Concomitant
medications had similar patterns in both cohorts, as anticoagulants and diuretics
were most frequently prescribed (registry 64%, 43%; chart 60%, 41%). Annualized
mortality rate was slightly higher in the registry (9.9%) compared to the chart
cohort (8.2%). Additional and complementary information was provided from chart
abstraction, including: Frequency of outpatient visits, medical procedures/exami-
nations and detailed clinical outcomes.CONCLUSIONS:Despite differences in data
sources, these cohorts showed overall similarity in demographic characteristics,
treatment patterns and clinical results. This approach supports the ability of sup-
plementing nationally available register data with patient level data in order to
broadly describe the burden of rare diseases like CTEPH.
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